Roles of the C Termini of alpha -, beta -, and gamma -Subunits of Epithelial Na+ Channels (ENaC) in Regulating ENaC and Mediating Its Inhibition by Cytosolic Na+*

Anuwat DinudomDagger , Kieran F. Harvey§, Permsak KomwatanaDagger , Corina N. Jolliffe§, John A. YoungDagger , Sharad Kumar§||, and David I. CookDagger ||**

From the Dagger  Department of Physiology, University of Sydney, New South Wales 2006, Australia and the § Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Frome Road, Adelaide, South Australia 5000, Australia

Received for publication, December 14, 2000, and in revised form, February 1, 2001




    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The amiloride-sensitive epithelial Na+ channels (ENaC) in the intralobular duct cells of mouse mandibular glands are inhibited by the ubiquitin-protein ligase, Nedd4, which is activated by increased intracellular Na+. In this study we have used whole-cell patch clamp methods in mouse mandibular duct cells to investigate the role of the C termini of the alpha -, beta -, and gamma -subunits of ENaC in mediating this inhibition. We found that peptides corresponding to the C termini of the beta - and gamma -subunits, but not the alpha -subunit, inhibited the activity of the Na+ channels. This mechanism did not involve Nedd4 and probably resulted from the exogenous C termini interfering competitively with the protein-protein interactions that keep the channels active. In the case of the C terminus of mouse beta -ENaC, the interacting motif included beta Ser631, beta Asp632, and beta Ser633. In the C terminus of mouse gamma -ENaC, it included gamma Ser640. Once these motifs were deleted, we were able to use the C termini of beta - and gamma -ENaC to prevent Nedd4-mediated down-regulation of Na+ channel activity. The C terminus of the alpha -subunit, on the contrary, did not prevent Nedd4-mediated inhibition of the Na+ channels. We conclude that mouse Nedd4 interacts with the beta - and gamma -subunits of ENaC.




    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The epithelial Na+ channel (ENaC)1 (1) is a major protein supporting the transepithelial transport of Na+ in many epithelia, including the renal collecting duct, the descending colon, the salivary ducts, and the respiratory epithelium (2, 3). It plays an important role in the regulation of blood pressure (4) and of fluid balance across the respiratory tract (5). Activating mutations in these channels, such as those found in the autosomal dominant form of hereditary hypertension known as Liddle's syndrome, produce hypertension both in humans (6) and in mouse models (7). Conversely, inactivating mutations produce salt-sensitive hypotension and fluid accumulation in the respiratory tract (8-10).

The C termini of each of the three subunits of ENaC contain PY motifs that bind the ubiquitin-protein ligase, Nedd4 (11-13). Nedd4 then ubiquitinates the Na+ channel (14-16) leading to its endocytosis (17) and degradation (16). Thus, mutation or deletion of the PY motifs leads to increased surface expression of Na+ channels in the Xenopus oocyte expression system (15, 18-20) and in renal epithelial cells (21). Furthermore, over-expression of wild-type Nedd4 reduces Na+ channel activity in Xenopus oocytes (15, 22), whereas over-expression of a Nedd4 mutant that is inactive as a ubiquitin protein ligase leads to increased Na+ channel activity (15, 22). The binding of Nedd4 to the PY motifs in the Na+ channel has also been proposed as a prerequisite for the insertion of the channels into the cell membrane in response to increased intracellular cyclic AMP (23).

The interaction between Nedd4 and Na+ channels appears to be regulated. Increased intracellular Na+ triggers the inactivation of Na+ channels by Nedd4 in Xenopus oocytes (20, 24-26) and in mouse salivary duct cells (14, 27-29). The importance of this regulation is evident from the finding that Liddle's syndrome is induced by the deletion or mutation of the PY motifs in the C termini of the beta - or gamma -subunits (6, 30-33). Yet little is known of the mechanism by which Nedd4 binds to ENaC. WW1, one of the three WW domains present in mouse Nedd4, does not bind any of the subunits of the epithelial Na+ channel (29), and the same observation has been made for the WW1 domain of human Nedd4 (11). Given that all three subunits of the Na+ channel, alpha , beta , and gamma , contain PY motifs in their C termini, this finding raised the question of whether the remaining two WW domains in mouse Nedd4 bind all three subunits of the Na+ channel indiscriminately or whether they bind specifically to only two of them. The available information that might have resolved this question is contradictory. Thus, although no cases of Liddle's syndrome have been reported to be caused by the deletion or mutation of the PY motif in the alpha -subunit (4), deletion of the C terminus of the alpha -subunit does lead to increased ENaC activity in Xenopus oocytes (33).

We investigated this question in mouse mandibular duct cells which, like the cells of other aldosterone-sensitive epithelia (34, 35), express all three subunits of ENaC (3, 29) and contain an amiloride-sensitive Na+ conductance that is activated by aldosterone (35). This amiloride-sensitive Na+ conductance is inhibited by increased intracellular Na+ acting via a Nedd4-mediated mechanism (14, 29). In the present study we used whole-cell patch clamp methods to examine whether the inclusion in the pipette solution of fusion proteins and synthetic peptides corresponding to the C termini of the alpha -, beta -, and gamma -subunits of the epithelial Na+ channel could prevent down-regulation of Na+ channel activity in mouse mandibular duct cells. We found that the C termini of beta - and gamma -ENaC, but not of alpha -ENaC, are able to prevent inhibition of Na+ channel activity by raised intracellular Na+.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Expression Plasmids-- The regions encoding the C termini of human and mouse alpha -, beta -, and gamma -ENaC subunits were polymerase chain reaction-amplified and cloned into either BamHI or BamHI/EcoRI sites of pGEX-2TK. Mouse C terminus beta -ENaC-10, mouse C terminus gamma -ENaC-10, and mouse C terminus gamma -ENaC-19 were polymerase chain reaction-amplified and cloned into the BamHI/EcoRI sites of pGEX-2TK. Human beta -ENaC PPNA, human gamma -ENaC S637G, and mouse gamma -ENaC PPRA and S643G mutants were generated by quick-change mutagenesis (Stratagene). Mouse alpha -, beta -, and gamma -ENaC subunit cDNAs were cloned from mouse mandibular duct cells as previously described (29) and found to be identical with the published sequences (36). Human a-, beta -, and gamma -ENaC cDNA clones were the gift of Dr. M. Welsh (University of Iowa).

Production of GST Fusion Proteins-- Overnight cultures of Escherichia coli DH5alpha harboring the appropriate GST expression plasmid were diluted 1/50, incubated for 2 h at 37 °C, induced with 1 mM isopropyl beta -D-thiogalactoside, and incubated for an additional 5 h at 37 °C. Bacterial cell pellets were resuspended in phosphate-buffered saline, lysed by sonication, and clarified by centrifugation at 10,000 × g for 10 min. Glutathione-Sepharose (Amersham Pharmacia Biotech) was incubated with the cleared lysate for 60 min at room temperature, after which the beads were washed three times with phosphate-buffered saline. Fusion protein was eluted with glutathione buffer according to the manufacturer's protocol. Protein concentration was measured using a BCA kit (Pierce). Fusion proteins were routinely checked by electrophoresis of 3 µg of the protein on a 12% SDS-polyacrylamide gel, which was then stained by Coomassie Blue (data not shown). In accordance with our usual practice, for the protein concentrations quoted in this paper, compensation was made for the presence of contaminating proteins (29).

Whole-cell Patch Clamping-- Isolated granular duct cells were prepared by collagenase digestion of mouse mandibular glands from male mice as described previously (37). The standard bath solution (pH 7.4) contained 145 mM NaCl, 5.5 mM KCl, 1 mM CaCl2, 1.2 mM MgCl2, 1.2 mM NaH2PO4, 7.5 mM HEPES, and 10 mM glucose. The standard (zero Na+) pipette solution (pH 7.2) contained 150 mM NMDG-glutamate, 5 mM NMDG-Cl, 1 mM MgCl2, 10 mM HEPES, 5 mM EGTA, and 10 mM glucose. In the 70 mM Na+ pipette solution, the Na+ concentration was adjusted by substituting sodium glutamate for NMDG-glutamate. Standard whole-cell patch clamp techniques were used (37, 38). After establishing the whole-cell configuration, we replaced the bath solution with one containing 145 mM sodium glutamate, 5 mM NaCl, 1 mM MgCl2, 10 mM HEPES, 1 mM EGTA, and 10 mM glucose (pH 7.4). The amiloride-sensitive current was measured as described previously (37, 38). The chord conductance was measured between -80 mV and the zero-current potential of the amiloride-sensitive current (37). The results are expressed as the mean ± S.E. Statistical significance was assessed using Student's unpaired t test. All experiments were performed at 20-22 °C.

Pertussis Toxin-- Pertussis toxin was stored as a 111 µg/ml stock solution. It was activated prior to use by incubation with 5 mM dithiothreitol for 15 min at 35 °C. It was then diluted to 500 ng/ml in pipette solution to which 1 mM nicotinamide adenine nucleotide had been added.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The C Termini of beta -ENaC and gamma -ENaC, but Not alpha -ENaC, Reduce Na+ Channel Activity Independently of Feedback Inhibition-- Prior to examining the effect of the C-terminal fusion proteins (Fig. 1) on Na+ feedback inhibition of the Na+ channels, we checked whether they affected Na+ channel activity when the Na+ feedback system is inactive. We did so by including 300 µg of each GST fusion protein ml in the zero Na+ pipette solution and then observing the effect of the fusion protein on the amiloride-sensitive Na+ current. To our surprise, we found that both the fusion protein containing the C terminus of human beta -ENaC and that containing the C terminus of mouse gamma -ENaC inhibited the amiloride-sensitive Na+ current (Fig. 2). The fusion protein containing the C terminus of mouse alpha -ENaC, however, did not have this effect (Fig. 2).



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 1.   Amino acid sequences of the C termini used in this study. The PY motifs present in alpha -, beta -, and gamma -ENaC are underlined. The SH3-binding domain present in alpha -ENaC is indicated by shading. The residues that are identical between the human and mouse proteins are shown in bold. *, termination codon.



View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   The C termini of beta - and gamma -ENaC inhibit the amiloride-sensitive Na+ conductance. This figure shows the effects on the chord conductance of the amiloride-sensitive Na+ current of including in the zero Na+ pipette solution the GST fusion proteins of the C termini of alpha -, beta -, or gamma -ENaC at a concentration of 300 µg/ml. The number of experiments is shown in parentheses.

Identification of the Motif Responsible for the Feedback-independent Inhibitory Action of the C Terminus of beta -ENaC-- We first investigated the basis of the inhibitory activity of the C terminus of beta -ENaC. We found that a fusion protein containing the C terminus of human beta -ENaC, in which the PY motif (PPNY) had been mutated (PPNA) so that it no longer interacted with Nedd4 (29), was still inhibitory (Fig. 3). Furthermore, inclusion of the C terminus of mouse beta -ENaC in the pipette solution together with a dominant negative mutant of ubiquitin (K48R), which we have previously shown to block inhibition of Na+ channels by increased intracellular Na+ in these cells (14), failed to prevent the inhibition produced by the C terminus of mouse beta -ENaC. Because inclusion of the K48R mutant of ubiquitin in zero Na+ pipette solution is not itself inhibitory (14), we concluded that the inhibition produced by the C terminus beta -ENaC does not involve ubiquitination of the Na+ channel. Deletion of 10 amino acids from the C terminus of the mouse beta -ENaC fusion protein, however, prevented the inhibitory effect of the fusion protein (Fig. 3), suggesting that the inhibitory motif is present in the last 10 amino acids of the beta -subunit.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 3.   Localization of the inhibitory domains of the C termini of beta -ENaC. The effects are shown on the chord conductance of the amiloride-sensitive Na+ current of the inclusion in the zero Na+ pipette solution of 300 µg/ml GST-beta -ENaC fusion protein in which the PY motif had been mutated to PPNA, of a mixture of 300 µg/ml control GST-beta -ENaC fusion protein and 300 µg/ml K48R mutant ubiquitin, or of 300 µg/ml GST-beta -ENaC fusion protein in which the final 10 amino acids of beta -ENaC had been deleted. The number of experiments is shown in parentheses, and the chord conductance observed with the control zero Na+ pipette solution is shown as a broken line.

We confirmed these findings by using synthetic peptides corresponding to the final 10 amino acids of mouse beta -ENaC (Fig. 4A). We found that the inclusion of 20 µM beta C10 peptide in the zero Na+ pipette solution inhibited the amiloride-sensitive Na+ current almost completely (Fig. 4B). We then investigated whether the action of the peptide was mediated by a pertussis toxin-sensitive G protein, because these are known to inhibit amiloride-sensitive Na+ channels (37, 39). We found, however, that the inclusion of activated pertussis toxin in the peptide solution did not prevent its inhibitory action on the Na+ channel (Fig. 4B). Finally, we investigated the effects of peptides based on beta C10 in which residues that may have been involved in the inhibitory motif were substituted by glycine (Fig. 4C). Initially we examined two peptides in which we had made double substitutions. One of these, beta E636G/I638G, in which we replaced the glutamate and isoleucine residues at positions 8 and 10 of the peptide (Fig. 4A) to target a possible PDZ-binding domain at the C terminus (40), retained its inhibitory activity (Fig. 4C). The other peptide, beta D632G/S633G (Fig. 4A), was without inhibitory activity (Fig. 4C). We further found that the inhibitory effect of the beta C10 peptide was completely abolished by substituting glycine for the serine residues at positions 3 (peptide beta S631G in Fig. 4A) or 5 (peptide beta S633G in Fig. 4A). Substituting glycine for the aspartate residue at position 4 (beta D632G in Fig. 4A), which lies between the two serine residues, reduced (p < 0.05), but did not abolish (p < 0.05) the inhibitory action of the peptide (Fig. 4C).



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 4.   Investigation of the inhibitory motif in the C terminus of beta -ENaC. A, amino acid sequences of the synthetic peptides used in this study. B, effects of 20 µM beta C10 peptide and of a mixture of 20 µM beta C10 peptide with 500 ng/ml activated pertussis toxin on the chord conductance of the amiloride-sensitive Na+ current when added to zero Na+ pipette solution. C, effects of the synthetic peptides described in panel A on the chord conductance of the amiloride-sensitive Na+ current when added to the zero Na+ pipette solution. In panels B and C, the number of experiments is given in parentheses, and the mean chord conductance of the amiloride-sensitive Na+ current observed using the control zero Na+ pipette solution is shown as a broken line.

Identification of the Motif Responsible for the Feedback-independent Inhibitory Action of the C terminus of gamma -ENaC-- We then investigated the basis of the inhibitory action of the C terminus of mouse gamma -ENaC. We found that mutation of the PY motif of mouse gamma -ENaC (PPRA) did not alter the inhibitory activity of the fusion protein (Fig. 5), indicating that the inhibition was not caused by activation of the feedback inhibitory system mediated by Nedd4. In contrast to our findings with the C terminus of mouse beta -ENaC, deletion of the terminal 10 amino acids of mouse gamma -ENaC did not remove the inhibitory effect of this fusion protein on the Na+ channel (Fig. 5). Only when we removed 19 amino acids from the C terminus of mouse gamma -ENaC did the fusion protein cease to inhibit the amiloride-sensitive Na+ current (Fig. 5).



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5.   Localization of the inhibitory domains of the C termini of gamma -ENaC. The effects are shown on the chord conductance of the amiloride-sensitive Na+ current of the inclusion in the zero Na+ pipette solution of 300 µg/ml GST-gamma -ENaC fusion protein in which the PY motif had been mutated to PPRA, 300 µg/ml GST-gamma ENaC fusion protein in which the final 10 amino acids of gamma -ENaC had been deleted, or 300 µg/ml GST-gamma ENaC fusion protein in which the final 19 amino acids of gamma -ENaC had been deleted. The number of experiments is shown in parentheses, and the chord conductance observed with the control zero Na+ pipette solution is shown as a broken line.

The experiments with GST fusion proteins suggested that the region between 10 and 19 residues from the C terminus of mouse gamma -ENaC contained the inhibitory motif. We therefore investigated whether a chemically synthesized peptide corresponding to this region (gamma mC9 in Fig. 6A) was inhibitory when included in the zero Na+ pipette solution, and we found that it was (Fig. 6B). Substituting the three serine residues (gamma Ser640, gamma Ser643, and gamma Ser644) in this peptide by glycines (gamma Ser right-arrow Gly) removed this inhibitory activity (gamma S-G in Fig. 6B). We then found that a peptide in which Ser640 was substituted by glycine (gamma S640G in Fig. 6A) was without inhibitory activity (Fig. 6B), whereas a peptide in which serines 643 and 644 are replaced by glycines (gamma S643G/S644G in Fig. 6A) was still inhibitory (Fig. 6B). Thus, serine 640 is required for the inhibitory activity of the C terminus of mouse gamma -ENaC.



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 6.   Investigation of the inhibitory motif in the C terminus of mouse gamma -ENaC. A, amino acid sequences of the synthetic peptides used in this study. B, effects of the synthetic peptides described in panel A on the chord conductance of the amiloride-sensitive Na+ current when added to the zero Na+ peptide solution. In panel B, the number of experiments is given in parentheses, and the mean chord conductance of the amiloride-sensitive Na+ current observed using the control zero Na+ pipette solution is shown as a broken line.

The Basis for the Feedback-independent Inhibitory Activity of Human gamma -ENaC-- Serine 640 in mouse gamma -ENaC is not present in human gamma -ENaC where it is replaced by an arginine residue (Fig. 7A). We thus expected that a GST fusion protein corresponding to the C terminus of human gamma -ENaC would not be inhibitory when included in the zero Na+ pipette solution (Fig. 7A). We found, however, that it did inhibit the amiloride-sensitive Na+ current (Fig. 7B). We thus investigated the effect of mutating the sole serine in the C terminus of human gamma -ENaC to glycine (gamma hS637G). We found that this mutant no longer inhibited the amiloride-sensitive Na+ current when included in zero Na+ pipette solution (Fig. 7B). Mutation of this serine in the C terminus of mouse gamma -ENaC, however, did not remove the inhibitory activity of the C terminus of mouse gamma -ENaC (Fig. 7B). This was consistent with our earlier findings using chemically synthesized peptides (see above and Fig. 6B).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 7.   The C terminus of human gamma -ENaC inhibits the amiloride-sensitive Na+ conductance. A, sequences of the fusion proteins used in Fig. 8B. B, the effects on the chord conductance of the amiloride-sensitive Na+ current of including in the zero Na+ pipette solution the GST fusion proteins shown in panel A at a concentration of 300 µg/ml. The number of experiments is given in parentheses, and the mean chord conductance of the amiloride-sensitive Na+ current observed using the control zero Na+ pipette solution is shown as a broken line.

A Peptide Including the beta -ENaC PY Motif Blocks Na+ Feedback Inhibition-- As outlined in the Introduction, we wished to determine whether mouse Nedd4 interacts with all three subunits of the epithelial Na+ channel or just two of them. We decided to do this by investigating whether inclusion in the patch pipette of GST fusion proteins of the C termini of alpha -ENaC, beta -ENaC, or gamma -ENaC (Fig. 1) could block the inactivation of Na+ channels induced by raised intracellular Na+, which in mouse mandibular duct cells is known to be mediated by Nedd4 (14). This experimental strategy was based on the idea that Nedd4 in salivary duct cells would bind exogenous PY motifs, which would then prevent its normal interaction with, and inhibition of, Na+ channels. We tested this idea by examining whether a synthetic peptide that included the PY motif of beta -ENaC (Fig. 8A) could block inhibition of the Na+ channels by increased intracellular Na+. As is evident from Fig. 8B, it does so with a half-maximal concentration of 0.3 µM.



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 8.   Use of a peptide containing the PY motif of mouse beta -ENaC to prevent inhibition of Na+ channels by cytosolic Na+. A, amino acid sequence of the synthetic peptide. The PY motif is shown in bold. B, concentration-response curve for the effect of the peptide on the chord conductance of the amiloride-sensitive Na+ current when the pipette contained the high (70 mM) Na+ solution. The number of experiments is shown in parentheses. For ease of comparison, the chord conductance of the amiloride-sensitive Na+ current measured using the zero Na+ pipette solution is shown as a broken line.

The C Termini of beta - and gamma - but not alpha -ENaC Inhibit Regulation of Na+ Channels by Increased Intracellular Na+-- We then proceeded to investigate whether the ENaC C termini interrupted control of the Na+ channels by intracellular Na+. We found that we could prevent the inhibitory action of the 70 mM Na+ pipette solution by including in it the C terminus of mouse beta -ENaC with the last 10 amino acids deleted (Fig. 9). To confirm that this effect was due to the PY motif in this construct, we also investigated the effect of this construct following mutation of the tyrosine in the PY motif to an alanine residue (beta mENaC-10 PY-mut). We have previously shown that this mutation eliminates the binding of the C terminus of mouse beta -ENaC to Nedd4 (29). We found that the mutant construct no longer prevented feedback inhibition of the amiloride-sensitive Na+ current (Fig. 9). We also found that the C terminus of mouse gamma -ENaC with the last 19 amino acids deleted prevented the inhibition of the amiloride-sensitive Na+ current by raised intracellular Na+ (Fig. 9). Once again, mutation of the construct by substitution of the tyrosine in the PY motif by alanine to eliminate its capacity to bind Nedd4 (29) rendered the fusion protein incapable of preventing Na+ feedback inhibition (Fig. 9). Finally, inclusion of the C terminus of mouse alpha -ENaC in the 70 mM Na+ pipette solution failed to prevent the down-regulation of the amiloride-sensitive Na+ current (Fig. 9).



View larger version (23K):
[in this window]
[in a new window]
 
Fig. 9.   The C termini of beta - and gamma - but not alpha -ENaC inhibit Na+-dependent feedback. Effects on the chord conductance of the amiloride-sensitive Na+ current of the inclusion of the ENaC C termini fusion proteins (300 µg/ml) in the 70 mM Na+ pipette solution. The number of experiments is given in parentheses, and the mean chord conductance of the amiloride-sensitive Na+ current observed using the control zero Na+ pipette solution is shown as a broken line.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

This study has shown that peptides and fusion proteins containing the PY motifs of beta - and gamma -ENaC prevent inhibition by increased intracellular Na+ of the amiloride-sensitive Na+ current in mouse mandibular duct cells. Na+-feedback inhibition of Na+ channels in mouse mandibular duct cells has previously been shown to be blocked by: (i) antibodies directed against mouse Nedd4, (ii) a mutant of mouse Nedd4 containing the WW domains but no HECT (ubiquitin-protein ligase) domain, and (iii) a dominant negative mutant of ubiquitin (14, 29), indicating that the Na+ feedback inhibition is mediated by Nedd4, which is expressed in these cells (14). Thus, the present findings show that the interaction of mouse Nedd4 with amiloride-sensitive Na+ channels can be blocked by PY motifs derived from the beta - and gamma -subunits of ENaC. Presumably these act by competing with the PY motifs in the native beta - and gamma -subunits of ENaC, thus preventing the normal interaction of Nedd4 with the Na+ channels.

On the other hand, we found that the C terminus of alpha -ENaC was unable to block Na+ feedback regulation of the amiloride-sensitive Na+ current. This fusion protein is evidently unable to compete with the endogenous Na+ channels for binding of Nedd4. Given that the alpha -subunits of rat, human, and mouse ENaC have all been shown to bind Nedd4 in vitro (11, 12, 29), this indicates that in vivo there must be some constraint on the interaction of the PY motif of the alpha -subunit of the channel with Nedd4. Consistent with this possibility is the report that the C terminus of alpha -ENaC is bound to alpha -spectrin in Madin-Darby canine kidney cells (41). The binding of alpha -spectrin is mediated by an SH3 (Src homology 3)-binding domain that overlaps the PY motif in alpha -ENaC (Fig. 1) and is not present in beta - or gamma -ENaC.

As explained in the Introduction, the WW1 domains of mouse and human Nedd4 do not bind any of the subunits of ENaC (11, 29). In the case of mouse Nedd4, which has only three WW domains, this raises the question of whether WW2 and WW3 bind to all three subunits of the Na+ channel or to only a subset of them. The present results demonstrate that WW2 and WW3 bind only to the beta - and gamma -subunits of the channel in vivo. Given that we have previously shown that the sites recognized by WW2 and WW3 in ENaCs from mouse salivary cells are distinct and are able to distinguish between WW2 and WW3 (29), it would thus appear likely that the WW2 of Nedd4 binds beta -ENaC and the WW3 of Nedd4 binds gamma -ENaC or vice versa. From the present data we cannot distinguish these possibilities.

The other major finding of our study is that the exogenous C termini of both the beta - and gamma -subunits of the Na+ channel inhibit Na+ channel activity. As argued below, this probably occurs because the exogenous C termini compete with the Na+ channels to interact with a protein, perhaps a kinase, that is required to maintain channel activity. In the case of the C terminus of mouse beta -ENaC, this motif is located in the final 10 amino acids and requires the presence of both of the serine residues present in this peptide, beta Ser631 and beta Ser633, as well as the aspartate residue between them, beta Asp632. In the case of the C terminus of mouse gamma -ENaC, the motif is in the region between 10 and 19 residues from the C terminus, and requires the presence of only one of the three serine residues present in this region, gamma Ser640. We further found that the C terminus of human gamma -ENaC inhibits the amiloride-sensitive Na+ current. This inhibition requires the presence of the serine gamma Ser637, the only serine present in the C terminus of human gamma -ENaC. Interestingly, the corresponding serine in mouse gamma -ENaC is not involved in inhibiting the amiloride-sensitive Na+ current (Fig. 7).

Consistent with our present findings, it has been reported previously that deletion of the C-terminal 8 amino acids of beta -ENaC increases Na+ channel activity in Xenopus oocytes (21), although a subsequent study in which the final 10 amino acids were deleted from beta -ENaC failed to observe any stimulation (33). It has also been reported that the constitutively activated Na+ channels obtained from lymphocytes of subjects with Liddle's syndrome can be blocked by the application of peptides that include the final 10 amino acids of the C terminus of beta -ENaC (42). This inhibition was attributed to the marked negative charge of the terminal decapeptide of beta -ENaC, because a peptide in which the four negatively charged residues found in it had been substituted by uncharged residues was inactive (42). The four negative charges mutated in the lymphocyte studies included, however, beta Asp632, which we have shown in the present study to be required for the inhibitory activity of the C terminus of beta -ENaC. Furthermore, we have found that mutation of beta Glu636 to an uncharged residue does not impair the inhibitory activity of the C-terminal peptide of beta -ENaC (42).

The mechanism by which the C termini of the beta - and gamma -C subunits inhibit the Na+ channels is unclear. For the C termini of both beta -ENaC and gamma -ENaC, we can exclude any role for binding of Nedd4. In the case of beta -ENaC, we can also exclude any role for ubiquitination or pertussis toxin-sensitive G proteins, which are known to inhibit Na+ channels in these and other cell types (14, 37, 39). Finally, the small size of the inhibitory regions of the C termini make it unlikely that they are forming a beta -pleated sheet and hence blocking the channel pore (43). Given the requirement for the presence of serine residues in the C termini of both beta -ENaC and gamma -ENaC and the report that these regions are constititutively phosphorylated in Madin-Darby canine kidney cells (44), it is tempting to postulate that the addition of exogenous beta -ENaC or gamma -ENaC C termini to the cytosol may be interfering in the phosphorylation processes required to maintain the channels in an active state. Consistent with this possibility is the observation that the C terminus of alpha -ENaC, which in the present studies is without inhibitory activity, is not phosphorylated in vivo (44).


    FOOTNOTES

* This project was supported by the National Health and Medical Research Council of Australia, the National Heart Foundation of Australia, and the Australian Kidney Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Wellcome Trust Senior Fellow in Medical Science.

|| These authors contributed equally to this work.

** Fellow of The Medical Foundation of the University of Sydney. To whom correspondence should be addressed: Dept. of Physiology (F-13), University of Sydney, NSW 2006, Australia. Fax: 61-2-9351-9926; E-mail: davidc@physiol.usyd.edu.au.

Published, JBC Papers in Press, February 1, 2001, DOI 10.1074/jbc.M011273200


    ABBREVIATIONS

The abbreviations used are: ENaC, epithelial Na+ channels; PY motif, PPXY sequence; GST, glutathione S-transferase; NMDG, N-methyl-D-glucamine.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Canessa, C. M., Schild, I., Buell, G., Thorens, B., Gautschi, I., Horisberger, J. D., and Rossier, B. C. (1994) Nature 367, 463-467[CrossRef][Medline] [Order article via Infotrieve]
2. Garty, H., and Palmer, L. G. (1997) Physiol. Rev. 77, 359-396[Abstract/Free Full Text]
3. Duc, C., Farman, N., Canessa, C. M., Bonvalet, J. P., and Rossier, B. C. (1994) J. Cell Biol. 127, 1907-1921[Abstract]
4. Hummler, E., and Horisberger, J. D. (1999) Am. J. Physiol. 276, G567-G571[Abstract/Free Full Text]
5. Matalon, S., and O'Brodovich, H. (1999) Annu. Rev. Physiol. 61, 627-661[CrossRef][Medline] [Order article via Infotrieve]
6. Shimkets, R. A., Warnock, D. G., Bositis, C. M., Nelson-Williams, C., Hansson, J. H., Scambelan, M., Gill, J. R., Ulick, S., Milora, R. V., Finling, J. W., Canessa, C. M., Rossier, B. C., and Lifton, R. P. (1994) Cell 79, 407-414[Medline] [Order article via Infotrieve]
7. Pradervand, S., Wang, Q., Burnier, M., Beermann, F., Horisberger, J. D., Hummler, E., and Rossier, B. C. (1999) J. Am. Soc. Nephrol. 10, 2527-2533[Abstract/Free Full Text]
8. Kerem, E., Bistritzer, T., Hanukoglu, A., Hofmann, T., Zhou, Z., Bennett, W., MacLaughlin, E., Barker, P., Nash, M., Quittell, L., Boucher, R., and Knowles, M. R. (1999) N. Engl. J. Med. 341, 156-162[Abstract/Free Full Text]
9. Barker, P. M., Nguyen, M. S., Gatzy, J. T., Grubb, B., Norman, H., Hummler, E., Rossier, B., Boucher, R. C., and Koller, B. (1998) J. Clin. Invest. 102, 1634-1640[Abstract/Free Full Text]
10. Strautnieks, S. S., Thompson, R. J., Gardner, R. M., and Chung, B. (1996) Nat. Genet. 13, 248-250[Medline] [Order article via Infotrieve]
11. Farr, T. J., Coddrington-Lawson, S. J., Snyder, P. M., and McDonald, F. J. (2000) Biochem. J. 345, 503-509[CrossRef][Medline] [Order article via Infotrieve]
12. Staub, O., Dho, S., Henry, P. C., Correa, J., Ishikawa, T., McGlade, J., and Rotin, D. (1996) EMBO J. 15, 2371-2380[Abstract]
13. Kumar, S., Tomooka, Y., and Noda, M. (1992) Biochem. Biophys. Res. Commun. 185, 1155-1161[Medline] [Order article via Infotrieve]
14. Dinudom, A., Harvey, K. F., Komwatana, P., Young, J. A., Kumar, S., and Cook, D. I. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7169-7173[Abstract/Free Full Text]
15. Goulet, C. C., Volk, K. A., Adams, C. M., Prince, L. S., Stokes, J. B., and Snyder, P. M. (1998) J. Biol. Chem. 273, 30012-30017[Abstract/Free Full Text]
16. Staub, O., Gautschi, I., Ishikawa, T., Breitschopf, K., Ciecanover, A., Schild, L., and Rotin, D. (1997) EMBO J. 16, 6325-6336[Abstract/Free Full Text]
17. Shimkets, R. A., Lifton, R. P., and Canessa, C. M. (1997) J. Biol. Chem. 272, 25537-25541[Abstract/Free Full Text]
18. Firsov, D., Schild, L., Gautschi, I., Merillat, A. M., Schneeberger, E., and Rossier, B. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 15370-15375[Abstract/Free Full Text]
19. Awayda, M. S., Tousson, A., and Benos, D. J. (1997) Am. J. Physiol. 273, C1889-C1899[Abstract/Free Full Text]
20. Kellenberger, S., Gautschi, I., Rossier, B. C., and Schild, L. (1998) J. Clin. Invest. 101, 2741-2750[Abstract/Free Full Text]
21. Snyder, P. M., Price, M. P., McDonald, F. J., Adams, C. M., Volk, K. A., Zeiher, B. G., Stokes, J. B., and Welsh, M. J. (1995) Cell 83, 969-978[Medline] [Order article via Infotrieve]
22. Abriel, H., Loffing, J., Rebhun, J. F., Pratt, J. H., Schild, L., Horisberger, J. D., Rotin, D., and Staub, O. (1999) J. Clin. Invest. 103, 667-673[Abstract/Free Full Text]
23. Snyder, P. M. (2000) J. Clin. Invest. 105, 45-53[Abstract/Free Full Text]
24. Huber, M., Schreiber, R., Boucherot, A., Sanchez-Perez, A., Poronnik, P., Cook, D. I., and Kunzelmann, K. (1999) FEBS Lett. 459, 443-447[CrossRef][Medline] [Order article via Infotrieve]
25. Awayda, M. S. (1999) Am. J. Physiol. 277, C216-C224[Abstract/Free Full Text]
26. Abriel, H., and Horisberger, J. D. (1999) J. Physiol. (London) 516, 31-43[Abstract/Free Full Text]
27. Komwatana, P., Dinudom, A., Young, J. A., and Cook, D. I. (1998) J. Membr. Biol. 162, 225-232[CrossRef][Medline] [Order article via Infotrieve]
28. Komwatana, P., Dinudom, A., Young, J. A., and Cook, D. I. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8107-8111[Abstract/Free Full Text]
29. Harvey, K. F., Dinudom, A., Komwatana, P., Joliffe, C. N., Day, M. L., Parasivam, G., Cook, D. I., and Kumar, S. (1999) J. Biol. Chem. 274, 12525-12530[Abstract/Free Full Text]
30. Tamura, H., Schild, L., Enomoto, N., Matsui, N., Marumo, F., Rossier, B. C., and Sasaki, S. (1996) J. Clin. Invest. 97, 1780-1784[Abstract/Free Full Text]
31. Hansson, J. H., Nelson-Williams, C., Suzuki, H., Schild, L., Shimkets, R., Lu, Y., Canessa, C., Iwasaki, T., Rossier, B., and Lifton, R. P. (1995) Nat. Genet. 11, 76-82[Medline] [Order article via Infotrieve]
32. Hansson, J. H., Schild, L., Lu, Y., Wilson, T. A., Gautschi, I., Shimkets, R. A., Nelson-Williams, C., Rossier, B. C., and Lifton, R. P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11495-11499[Abstract]
33. Schild, L., Lu, Y., Gautschi, I., Schneeberger, E., Lifton, R. P., and Rossier, B. C. (1996) EMBO J. 15, 2381-2387[Abstract]
34. Cook, D. I., Van Lennep, E. W., Roberts, M. L., and Young, J. A. (1994) in Physiology of the Gastrointestinal Tract (Johnson, L. , Christensen, J. , Jackson, M. , Jacobson, E. , and Walsh, J., eds), 3rd Ed., Vol. 2 , pp. 1061-1117, Raven Press, New York
35. Gruber, W. D., Knauf, H., and Frömter, E. (1973) Pflügers Arch. 344, 33-49[Medline] [Order article via Infotrieve]
36. Kosari, F., Sheng, S., Li, J., Mak, D. O., Foskett, J. K., and Kleyman, T. R. (1998) J. Biol. Chem. 273, 13469-13474[Abstract/Free Full Text]
37. Dinudom, A., Komwatana, P., Young, J. A., and Cook, D. I. (1995) J. Physiol. (London) 487, 549-555[Abstract]
38. Dinudom, A., Young, J. A., and Cook, D. I. (1993) Pflügers Arch. Eur. J. Physiol 423, 164-166[Medline] [Order article via Infotrieve]
39. Berdiev, B. K., Shlyonsky, V. G., Senyk, O., Keeton, D., Guo, Y., Matalon, S., Cantiello, H. F., Prat, A. G., Ausiello, D. A., Ismailov, I. I., and Benos, D. J. (1997) Am. J. Physiol. 272, C1262-C1270[Abstract/Free Full Text]
40. Schepens, J., Cuppen, E., Wieringa, B., and Hendriks, W. (1997) FEBS Lett. 409, 53-56[CrossRef][Medline] [Order article via Infotrieve]
41. Rotin, D., Bar-Sagi, D., O'Brodovich, H., Merilainen, J., Lehto, P. V., Canessa, C. M., Rossier, B. C., and Downey, G. P. (1994) EMBO J. 13, 4440-4450[Abstract]
42. Ismailov, I. I., Berdiev, B. K., Fuller, C. M., Bradford, A. L., Lifton, R. P., Warnock, D. G., Bubien, J. K., and Benos, D. J. (1996) Am. J. Physiol. 270, C214-C223[Abstract/Free Full Text]
43. Ismailov, I. I., Shlyonsky, V. G., Serpersu, E. H., Fuller, C. M., Cheung, H. C., Muccio, D., Berdiev, B. K., and Benos, D. J. (1999) Biochemistry 38, 354-363[CrossRef][Medline] [Order article via Infotrieve]
44. Shimkets, R. A., Lifton, R., and Canessa, C. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3301-3305[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.